微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 16.85% | 7.05% | -0.94% | 138/159 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 17.01% | -0.55% | -8.17% | 143/159 | 51.8% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 18.53% | -0.09% | -2.29% | 142/159 | 22.98% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 18.96% | 2.88% | 20.44% | 142/159 | 33.39% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 15.74% | 3.83% | -7.98% | 140/159 | 51.73% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 17.11% | 20.35% | -7.73% | 143/159 | 51.53% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 18.54% | 30.05% | 0.61% | 142/159 | 32.76% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 18.43% | 20.49% | 21.55% | 139/159 | 38.65% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 15.16% | 18.21% | 6.67% | 139/159 | 52.91% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 14.22% | -14.41% | -0.3% | 147/159 | 53.74% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 14.26% | -17.21% | -6.79% | 138/159 | 6.69% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 15.3% | -18.74% | 19.25% | 143/159 | 21.74% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 12.83% | 2% | -22.77% | 133/159 | 54.47% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 16.61% | -32.46% | -3.56% | 145/159 | 55.21% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 17.22% | 2% | -8.51% | 130/159 | 47.01% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 18.82% | -21.3% | -23.45% | 137/159 | 47.45% | 艾力斯 | 98.7% | 行业排名> |
| 2020-12-31 | 24.59% | 10.25% | 2.81% | 132/159 | -144.37% | 艾力斯 | 99.4% | 行业排名> |
| 2020-06-30 | 23.92% | 2% | 7.24% | 120/159 | 54.32% | 首药控股 | 99.94% | 行业排名> |
| 2019-12-31 | 22.3% | 7.41% | 7.41% | 130/159 | -1213.38% | 泽璟制药 | 99.96% | 行业排名> |
| 2018-12-31 | 20.77% | 7.9% | 7.9% | 129/159 | -205.91% | 微芯生物 | 95.14% | 行业排名> |
| 2017-12-31 | 19.24% | 2% | 2% | 119/159 | 52.58% | 多瑞医药 | 95.59% | 行业排名> |